"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products and key innovative products," said Teva CEO.

Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of 71 cents per share,

Teva Pharmaceutical (TEVA) stock falls as the generic drugmaker with its Q4 2024 results set its 2025 earnings outlook below consensus. Read more here.

Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit sales gains in a trio of its branded drugs to treat migraines, Huntington's disease and schizophrenia.